European Commercial RolloutEuropean commercial rollout advancing with the acceptance of PEDMARQSI for use in Scotland and launches in Germany, England, and Wales.
Intellectual Property And Orphan Drug StatusPedmark has IP protection until 2039 and orphan drug status until 2029, providing a competitive advantage in the market.
Market ExpansionFennec remains poised to reap benefits from market expansion to the adolescent and young adult (AYA) community with payor reimbursement, along with accelerating product adoption at key academic centers.